You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for PNU 96415E
PNU 96415E is an antipsychotic agent. Displays high affinity for dopamine D4 and serotonergic 5-HT2A receptors and relatively weak affinity at D2 receptors (Ki values are 3.0, 5.8, 134, 181, 199, 240, 411 and > 678 nM for D4, 5-HT2A, 5-HT1A, α1, D2, D3, D1, α2 and muscarinic receptors respectively). Inhibits exploratory locomotor activity and antagonizes d-amphetamine-induced locomotor stimulation in rats.
Technical Data for PNU 96415E
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for PNU 96415E
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for PNU 96415E
The following data is based on the product molecular weight 413.36. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||24.19 mL||120.96 mL||241.92 mL|
|0.5 mM||4.84 mL||24.19 mL||48.38 mL|
|1 mM||2.42 mL||12.1 mL||24.19 mL|
|5 mM||0.48 mL||2.42 mL||4.84 mL|
References for PNU 96415E
References are publications that support the biological activity of the product.
Tang et al (1997) PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J.Pharmacol.Exp.Ther. 281 440 PMID: 9103528
Goudie et al (1998) Discriminative stimulus properties of the atypical neuroleptic cloz. in rats: tests with subtype selective receptor ligands. Behav.Pharmacol. 9 699 PMID: 9890260
If you know of a relevant reference for PNU 96415E, please let us know.
View Related Products by Product Action
Keywords: PNU 96415E, PNU 96415E supplier, 5-HT2A, D4, antagonists, antipsychotic, Serotonin, Receptors, Dopamine, dopaminergic, PNU96415E, 2735, Tocris Bioscience
1 Citation for PNU 96415E
Citations are publications that use Tocris products. Selected citations for PNU 96415E include:
Dolma et al (2016) Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. Cancer Cell 29 859 PMID: 27300435
Do you know of a great paper that uses PNU 96415E from Tocris? Please let us know.
Reviews for PNU 96415E
There are currently no reviews for this product. Be the first to review PNU 96415E and earn rewards!
Have you used PNU 96415E?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.